Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity.

Singh S., Gleason CE., Fang M., Laimon YN., Khivansara V., Xie S., Durmaz YT., Sarkar A., Ngo K., Savla V., Li Y., Abu-Remaileh M., Li X., Tuladhar B., Odeh R., Hamkins-Indik F., He D., Membreno MW., Nosrati M., Gushwa NN., Leung SSF., Fraga-Walton B., Hernandez L., Baldomero MP., Lent BM., Spellmeyer D., Luna JF., Hoang D., Gritsenko Y., Chand M., DeMart MK., Metobo S., Bhatt C., Shapiro JA., Yang K., Dupper NJ., Bockus AT., Doench JG., Aggen JB., Liu L-F., Levin B., Wang EW., Vendrell I., Fischer R., Kessler B., Gokhale PC., Signoretti S., Spektor A., Kreatsoulas C., Singh R., Earp DJ., Garcia PD., Nijhawan D., Oser MG.

DOI

10.1101/2024.08.01.605889

Type

Preprint

Publication Date

01/08/2024

Permalink Original publication